GlassScriptPhysician profile
Carlos Perez
NPI 1669447256
$4,085.74
in general payments reported to CMS, 2019-2025
17 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $344 · 2021: $561 · 2022: $491 · 2023: $1,078 · 2024: $385 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $943.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.45 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $457.43 | 2019-2024 | Darzalex, Invokana, Xarelto |
| Glaxosmithkline, LLC. | $450.62 | 2019-2025 | Trelegy Ellipta |
| Eli Lilly Export S.A. Puerto Rico Branch | $350.00 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Lilly USA, LLC | $338.94 | 2020-2025 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $200.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $194.32 | 2019-2025 | Eliquis, Zeposia |
| Pbg Puerto Rico LLC | $179.75 | 2019-2021 | |
| Novo Nordisk INC | $150.29 | 2019-2020 | |
| Pfizer INC. | $74.05 | 2022-2023 | |
| Amgen INC. | $71.32 | 2019-2023 | Prolia, Repatha |
| Abbvie INC. | $70.06 | 2021-2023 | |
| Genmab U.S., INC. | $39.31 | 2024 | Epkinly |
| Morphosys, US INC. | $25.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.